Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL5436118 | 0.85 | — | — | |
| SCHEMBL2474882 | 0.82 | MEN1 (0.48) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| 1,4-Butanediol SCHEMBL1313386 | 0.80 | SMN1; SMN2 (0.41) | TSHRALDH1A1MEN1KMT2A | |
| 1,4-Butanediol SCHEMBL1313383 | 0.80 | SMN1; SMN2 (0.41) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL905351 | 0.79 | — | — | |
| SCHEMBL28643093 | 0.79 | — | — | |
| SCHEMBL75982 | 0.79 | — | — | |
| SCHEMBL28643095 | 0.79 | — | — | |
| SCHEMBL2961236 | 0.78 | TSHR (0.50) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL2968123 | 0.76 | MEN1 (0.52) | TSHRMAPK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434342-B1 | Method for producing curable composition for imprints | FUJIFILM CORP (JP) | 2018-06-20 | — | — | EP | disclosed |
| EP-2556532-B1 | CURABLE COMPOSITION FOR IMPRINTS AND PRODUCING METHOD OF POLYMERIZABLE MONOMER FOR IMPRINTS | FUJIFILM CORP (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-2342243-B1 | COMPOSITION FOR IMPRINTS, PATTERN AND PATTERNING METHOD | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9684233-B2 | Curable composition for imprints, patterning method and pattern | FUJIFILM CORPORATION (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9441065-B2 | Curable composition for imprints, cured product and method for manufacturing a cured product | FUJIFILM CORPORATION (JP) | 2016-09-13 | — | — | US | disclosed |
| US-8933144-B2 | Curable composition for imprint, pattern-forming method and pattern | FUJIFILM CORPORATION (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20140255662-A1 | CURABLE COMPOSITION FOR IMPRINT, PATTERN-FORMING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8703892-B2 | Curable composition for imprints, patterning method and pattern | FUJIFILM CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8530540-B2 | Curable composition for imprints, patterning method and pattern | FUJIFILM CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8282872-B2 | (Meth)acrylate compound, curable composition using the same, curable composition for photo-nanoimprints, cured product of curable composition and method for manufacturing cured product | FUJIFILM CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20120225263-A1 | CURABLE COMPOSITION FOR IMPRINTS, PATTERNING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2490072-A2 | Method for producing curable composition for imprints | Fujifilm Corporation (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2434342-A1 | Method for producing curable composition for imprints | FUJIFILM Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20110003909-A1 | (METH)ACRYLATE COMPOUND, CURABLE COMPOSITION USING THE SAME, CURABLE COMPOSITION FOR PHOTO-NANOIMPRINTS, CURED PRODUCT OF CURABLE COMPOSITION AND METHOD FOR MANUFACTURING CURED PRODUCT | FUJIFILM CORPORATION | 2011-01-06 | — | — | US | disclosed |
| EP-2244281-A1 | CURABLE COMPOSITION FOR NANOIMPRINT AND PATTERN-FORMING METHOD | FUJIFILM Corporation (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100009138-A1 | CURABLE COMPOSITION FOR IMPRINTS, PATTERNING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009287-A1 | CURABLE COMPOSITION FOR IMPRINTS, PATTERNING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009137-A1 | COMPOSITION FOR IMPRINTS, PATTERN AND PATTERNING METHOD | FUJIFILM CORPORATION (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20090011367-A1 | INTERFACE BINDER, RESIST COMPOSITION CONTAINING THE SAME, LAMINATE FOR FORMING MAGNETIC RECORDING MEDIUM HAVING LAYER CONTAINING THE SAME, MANUFACTURING METHOD OF MAGNETIC RECORDING MEDIUM USING THE SAME, AND MAGNETIC RECORDING MEDIUM PRODUCED BY THE MANUFACTURING METHOD | FUJIFILM CORPORATION (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003909-A1 | (METH)ACRYLATE COMPOUND, CURABLE COMPOSITION USING THE SAME, CURABLE COMPOSITION FOR PHOTO-NANOIMPRINTS, CURED PRODUCT OF CURABLE COMPOSITION AND METHOD FOR MANUFACTURING CURED PRODUCT | DNMT3A, DOT1L, PDE6D | TSHR 2573/4885MAPK1 2592/4885ALDH1A1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.